EDITORIAL / INDEPENDENT
About PT-141 Legit.
An independent editorial project publishing summaries of the peer-reviewed research literature on PT-141 / bremelanotide. We do not employ clinicians, we do not provide medical advice, and we do not manufacture, sell, or distribute any product.
What this site is
PT-141 Legit is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 / bremelanotide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The primary sources behind this digest are the FDA Vyleesi prescribing information [4][7], the two RECONNECT Phase 3 papers in Obstetrics & Gynecology (Kingsberg 2019, Simon 2019) [3][6], the integrated safety review (Clayton 2022) in Journal of Women's Health [5], the foundational pharmacology paper (Molinoff 2003) in Annals of the New York Academy of Sciences [1], the Pfaus 2004 PNAS rat solicitation study [10], the Diamond 2005 Urology male-ED intranasal study [9], the 2022 JCI mechanistic fMRI study (Thurston 2022) [17], and the Spielmans 2021 Journal of Sex Research independent re-analysis [14]. Every quantitative claim on the site resolves to one of these or twelve adjacent primary sources, listed in full on the PT-141 references and citations page.
The 'legit' in the domain
The domain modifier — 'legit' — names a position the publisher occupies relative to the literature, not a service the site offers. The visitor who arrives here is vetting whether PT-141 is what its sellers claim. Our editorial response is to publish the record — the FDA label, the pivotal trials, the independent re-analysis, the off-label literature, the adverse-event frequencies — and let the visitor read.
The site is not a vendor, not a clinical service, and not a referral source. We have no commercial relationship with the manufacturer of the approved product or with any research-peptide supplier. We do not accept paid placements or sponsored content. The numbered citations in the body text and the full list on PT-141 references and citations are the only authorities the site invokes.
What this site is not
This site does not provide medical advice. Nothing on this site should be construed as a recommendation to use, dose, source, or self-administer any compound. We do not have a clinical team, a medical director, a prescribing physician, or any other licensed healthcare professional on staff.
The FDA-approved product for hypoactive sexual desire disorder in premenopausal women is available by prescription in the United States [3][4][7]. Anyone considering it should consult a licensed prescribing clinician. Research-grade peptide marketed for laboratory use only is not the same product as the FDA-approved prescription product and is not regulated as a human medical product.